Evommune (EVMN) Return on Assets (2025 - 2026)

Evommune (EVMN) posted quarterly Return on Assets of 0.01% for Q1 2026, down 19.86% quarter-over-quarter from 0.01% in Q4 2025.

Evommune (EVMN) Return on Assets (2025 - 2026) Analysis & Trends

Evommune (EVMN) has reported Return on Assets for 2 consecutive years, with 0.01% the latest figure, recorded in Q1 2026.

In Q1 2026, Return on Assets changed N/A year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed N/A YoY), while the FY2025 annual figure was 0.01%, changed N/A from the prior year.
Return on Assets eased to 0.01% in Q1 2026 per EVMN's latest filing, from 0.01% in the prior quarter.
Across five years, Return on Assets topped out at 0.01% in Q4 2025 and bottomed at 0.01% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-0.01%
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Evommune	531.53 Mn	330.73 Mn	-	-0.01%

Download Data